Piramal Pharma soars on strong Q2 numbers

Piramal Pharma shares surged 12.37% to Rs 223 after the company reported consolidated net profit after tax of Rs 5 crore, compared with a net loss of Rs 99 crore in Q2 FY26.

Revenue from operations increased 28% year on year to Rs 2,617 crore from Rs 2,044 crore.

EBITDA climbed 72% year on year to Rs 385 crore from Rs 224 crore. The company said EBITDA margin expanded by 370 basis points to 14.7% in Q2 FY27, supported by higher capacity utilisation, operating leverage, disciplined execution and cost optimisation.

Pre-tax profit stood at Rs 82 crore in Q2 FY27, compared with a loss of Rs 46 crore in Q2 FY26.

Material costs rose 29% to Rs 906 crore from Rs 703 crore, while employee expenses increased 17% to Rs 714 crore from Rs 611 crore. Other expenses climbed 13% to Rs 648 crore from Rs 571 crore.

Piramal Pharma added 22 new customers and completed 12 regulatory inspections and 110 customer audits during H1 FY27. The company said it maintained its record of no Official Action Indicated classifications across US FDA inspections.

The company upgraded its FY27 revenue growth outlook to 19%-20%, citing strong first-half performance and continued business momentum.

Chairperson Nandini Piramal said the CDMO business grew 28% in H1 FY27, while the complex hospital generics business grew 24% and Consumer Healthcare recorded 14% growth.

Piramal Pharma operates through three businesses: Piramal Pharma Solutions, an integrated contract development and manufacturing organisation (CDMO); Piramal Critical Care, which focuses on complex hospital generics; and Piramal Consumer Healthcare, which offers over-the-counter and wellness products. The company operates 17 development and manufacturing facilities and serves more than 100 countries through its global distribution network. Its associate company, AbbVie Therapeutics India, is active in the ophthalmology segment of the Indian pharmaceutical market.

Powered by Capital Market - Live News